

Technology Advisory Interests Register

Topic: Amivantamab with carboplatin and pemetrexed for untreated EGFR exon 20 insertion mutation-positive advanced non-small-cell lung cancer [ID5110]

Publication Date: TBC

Name	Role with NICE	Type of interest	Description of interest	Interest declared	Comments
Giles Monnickendam	TAC Committee Member	Financial	Giles has received honoraria and consulting fees from Janssen Cilag Ltd and Janssen Global Services for attending advisory boards and providing advice for products in for relapsed refractory multiple myeloma.	23/01/2025 07/08/2025 10/10/2025	It was agreed that Giles's declaration would not prevent them from participating in discussions on this appraisal
David Meads	TAC Committee Member	Financial	I and the academic Unit I am director of have received funding from J&J for research in an unrelated area, relating to different technologies. The funding goes to the University of Leeds and not to me or my staff personally.	02/08/2025	It was agreed that David's declaration would not prevent them from participating in discussions on this appraisal
Simon McNamara	TAC Committee Member	Financial	GSK have an ongoing phase 3 trial of niraparib + pembrolizumab maintenance therapy following chemotherapy and pembrolizumab induction therapy for 1L metastatic non-small cell lung cancer (i.e., a first line maintenance study). This study excludes patients with EGFR	14/10/2025	It was agreed that Simon's declaration would not prevent them from participating in discussions on this appraisal

Name	Role with NICE	Type of interest	Description of interest	Interest declared	Comments
			mutations (i.e., the population for the second two topics).		
Will Sullivan	TAC Committee Member	Financial	Through my salaried role we're about to start a project with Johnson & Johnson, concerning their in-development treatment for geographic atrophy (an ophthalmological condition).	29/10/2025	It was agreed that Will's declaration would not prevent them from participating in discussions on this appraisal
Professor Sanjay Popat	Clinical Expert	Direct- financial	Sanjay has received honoraria as consultant to multiple companies in field of thoracic malignancy/genomics: Anheart, Amgen, AstraZeneca, Bayer, Blueprint, BMS, Boehringer Ingelheim, Daiichi Sankyo, EQRx, GlaxoSmithKline, Guardant Health, Janssen, Lilly, Merck KGaA, MSD, Novartis, Pfizer, PharmaMar, Roche, Sanofi, Takeda, Turning Point Therapeutics. Honoraria from Janssen totalling £3K included consultancy for this product and other licensed/unlicensed drugs/technologies.	31/07/2024 13/08/2025	It was agreed that Sanjay's declaration would not prevent them from providing expert advice to the committee
		Non-financial	Advisor to Charities: ALK Positive UK, Lung Cancer Europe, Ruth Strauss Foundation		

Name	Role with NICE	Type of interest	Description of interest	Interest declared	Comments
			Board of Directors: Mesothelioma Applied Research Foundation Leadership: BTOG Steering Committee Chair, ETOP Foundation Council Member		
Professor Gini Harrison	Expert	Financial	Research Trustee at EGFR+ UK who have received £3,508 from Janssen to cover some of our patient support activities.	07/08/2024 13/08/2025	It was agreed that Gini's declaration would not prevent them from providing expert advice to the committee